Wockhardt Ltd 2018 AR2
The report highlights Wockhardt Limited's performance and initiatives for the fiscal year 2017-18, focusing on its strategic research and development in pharmaceuticals, biotechnology, and New Chemical Entities (NCEs). The company advanced its clinical trials for five breakthrough antibacterial NCEs, all of which have been granted QIDP status by the US FDA. Wockhardt also received key regulatory approvals, including EU GMP certification for its Shendra site. Through the Wockhardt Foundation, the company continued its corporate social responsibility efforts, touching over 74 million lives through healthcare, education, and sanitation programs, including the flagship Mobile 1000 initiative.
Company: Wockhardt Ltd
Sector: Manufacturing
Country: India
Year: 2018
Type: AR2
Pages: 192
Back to company
Wockhardt Ltd
Annual Report
The report highlights Wockhardt Limited's performance and initiatives for the fiscal year 2017-18, focusing on its strategic research and development in pharmaceuticals, biotechnology, and New Chemical Entities (NCEs). The company advanced its clinical trials for five breakthrough antibacterial NCEs, all of which have been granted QIDP status by the US FDA. Wockhardt also received key regulatory approvals, including EU GMP certification for its Shendra site. Through the Wockhardt Foundation, the company continued its corporate social responsibility efforts, touching over 74 million lives through healthcare, education, and sanitation programs, including the flagship Mobile 1000 initiative.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees